TG Therapeutics, Inc. · TGTX · FY2026 Q3 · Calendar Q4 2026
TG Therapeutics raises 2026 revenue outlook as BRIUMVI momentum continues
The quarter's higher revenue outlook and management's account of increasing BRIUMVI adoption support a positive near-term commercial trajectory. Whether growth extends will depend on payer economics, competition, and execution of planned formulation and pipeline programs.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about TGTX FY2026 Q3
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Management raised full-year global revenue guidance to $1 billion and U.S. BRIUMVI guidance to $915–$920 million. The call also highlighted long-term BRIUMVI data and early results for subcutaneous BRIUMVI and azer-cel. Compared with the prior-quarter analysis, the guidance direction remains raised, with a higher current outlook.
Guidance delta
Raised: global full-year revenue guidance is now $1 billion, and U.S. BRIUMVI net revenue guidance is $915–$920 million. The prior-quarter analysis recorded global guidance of approximately $950 million and U.S. guidance of $890–$905 million.
Key takeaways
- Management cited physician adoption, hospital growth and treatment-naïve starts as commercial drivers.
- BRIUMVI long-term follow-up data and early subcutaneous results featured in the call.
- Early azer-cel results in progressive MS were described as encouraging, but the program remains investigational.
- The reported revenue result exceeded consensus while EPS was below consensus.
Management priorities
- Pursue approval and launch of the single-dose IV initiation regimen, targeted around mid-2027.
- Prepare for a subcutaneous BRIUMVI launch with an auto-injector, targeted for 2028.
- Advance azer-cel and studies in myasthenia gravis and schizophrenia; continue conference data presentations.
- Maintain disciplined capital allocation and return cash to shareholders.
Follow TGTX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | Outperform | Maintain | Nov 10, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Sep 1, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 7, 2026 |
| B. Riley Securities | Buy | Buy | Maintain | Jul 27, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Jul 7, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jan 15, 2026 |
| Ladenburg Thalmann | Buy | Buy | Maintain | May 2, 2024 |
| Jefferies | Buy | Buy | Maintain | Nov 1, 2023 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Feb 7, 2023 |
| HC Wainwright& Co. | Buy | Buy | Maintain | Aug 1, 2021 |
| B. Riley FBR | Buy | Buy | Maintain | Feb 9, 2021 |
| H.C. Wainwright | Buy | Buy | Maintain | Jan 17, 2020 |
| Raymond James | Outperform | Strong Buy | Downgrade | Sep 25, 2018 |
Named analyst price targets
Upside is calculated against the persisted current price $63.34. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| H.C. Wainwright | Emily Bodnar | $78 | $46.17 | +23.1% | Aug 4, 2026 |
| Jefferies | Analyst unavailable | $83 | $54.4 | +31.0% | Jun 22, 2026 |
| H.C. Wainwright | Analyst unavailable | $70 | $39.75 | +10.5% | May 6, 2026 |
| Goldman Sachs | Analyst unavailable | $39 | $29.54 | -38.4% | Jan 15, 2026 |
| H.C. Wainwright | Emily Bodnar | $60 | $36.7 | -5.3% | Oct 6, 2025 |
| H.C. Wainwright | Edward White | $27.5 | $12.93 | -56.6% | Nov 5, 2024 |
| Goldman Sachs | Corinne Jenkins | $20 | $20.58 | -68.4% | Aug 6, 2024 |
| H.C. Wainwright | Edward White | $24.5 | $8.21 | -61.3% | May 3, 2024 |
| Cantor Fitzgerald | Analyst unavailable | $24 | $18.48 | -62.1% | Feb 7, 2023 |
| Evercore ISI | Analyst unavailable | $16 | $11.83 | -74.7% | Dec 30, 2022 |
| H.C. Wainwright | Edward White | $12 | $4.23 | -81.1% | Dec 29, 2022 |
| Goldman Sachs | Analyst unavailable | $5 | $7.26 | -92.1% | Apr 19, 2022 |
| Telsey Advisory | Mayank Mamtani | $11.5 | $3.46 | -81.8% | Apr 18, 2022 |
Track every rating change on TGTX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationBased in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma.…
Historical context
All TGTX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ASND Ascendis Pharma A/S | FY2026 Q3 · Calendar Q4 2026 | +38.7% | +3.0% | Ascendis Q3 growth broadens the story, while execution risks remain |
| ALC Alcon Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.2% | -2.3% | Alcon holds FY outlook as new launches meet IOL competition |
Latest beats and misses
Who reports nextBeat on EPS
- INTUFY2027 Q1 · November 19, 2026+18.3% EPS-6.2% move
- ROSTFY2026 Q3 · November 19, 2026+2.1% EPS-2.8% move
- ESTCFY2027 Q2 · November 19, 2026+16.2% EPS+2.0% move
- KEYSFY2026 Q4 · November 19, 2026+7.1% EPS-1.5% move
- WSMFY2026 Q3 · November 19, 20260.0% EPS-15.2% move
- WMGFY2026 Q4 · November 19, 2026+50.9% EPS-0.6% move
Missed on EPS
- NTESFY2026 Q3 · November 19, 2026-12.8% EPS-11.4% move
- FUTUFY2026 Q3 · November 19, 2026-7.8% EPS+4.8% move
- BABAFY2027 Q2 · November 19, 2026-29.2% EPS-1.3% move
- SQMFY2026 Q3 · November 17, 2026-3.0% EPS-5.5% move
- VIKFY2026 Q3 · November 17, 2026-12.6% EPS+4.4% move
- XPFY2026 Q3 · November 16, 2026-3.0% EPS-2.5% move
Get the TGTX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-10T00:12:30.985967+00:00
- FN2 earnings calendar · 2026-11-12T01:23:14.140288+00:00
- Polygon adjusted daily market bars · 2026-11-12T01:40:42.573310+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-12T01:40:42.570688+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-12. For educational purposes only; not investment advice.